Ligelizumab for Chronic Spontaneous Urticaria

Abstract

To the Editor: Maurer et al. (Oct. 3 issue)¹ report on a phase 2b dose-finding trial examining the efficacy of ligelizumab in the treatment of chronic spontaneous urticaria. They found that ligelizumab outperformed omalizumab, and the maximum effect was observed at a dose of 72 mg. The authors controlled for the Chronic Urticaria Index (CU Index) score in analyses of secondary end points. However, they did not stratify the effect according to a positive CU Index or the degree to which the IgE level was elevated at baseline. Although it would be a post hoc analysis, it would be interesting . . .